Trelegy Ellipta general drug use investigation (asthma)

Study identification

• EU PAS number:
  EUPAS40313
• Study ID:
  44600
• Official title and acronym:
  Trelegy Ellipta general drug use investigation (asthma)
• DARWIN EU® study:
  No
• Study countries:
  Japan
• Study description:
  Post-marketing surveillance to collect and assess information regarding the safety and effectiveness of Trelegy Ellipta in asthma patients under the actual use conditions.
• Study status:
  Finalised

Research institutions and networks

Institutions

GlaxoSmithKline (GSK)

Study timelines

Date when funding contract was signed

Actual:08/07/2021

Study start date

Planned:30/07/2021

Actual:08/07/2021

Date of final study report

Planned:31/12/2024

Actual:08/11/2024

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

GlaxoSmithKline

Regulatory

• Was the study required by a regulatory body?:
  Yes
• Is the study required by a Risk Management Plan (RMP)?:
  Non-EU RMP only